Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises HealthCap in conjunction with its investment in Elsa Science
Mandate

Vinge advises HealthCap in conjunction with its investment in Elsa Science

November 05, 2021 M&A

Vinge has advised HealthCap in conjunction with its investment in Elsa Science, which develops an app that provides patients suffering from rheumatoid arthritis to receive tailormade treatment.

The financing round is headed by Healthcap and also existing investors such as the Finnish venture capital company Inventure, Crowberry Capital from Iceland, Norrsken VC as well as Noaber from the Netherlands.

Vinge’s team primarily consisted of Johan Winnerblad, Stina Bengtsson, Hannah Kajlinger and Lisa Hörnqvist.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025